Introduction Le cancer de la prostate incident est une découverte fortuite lors d’une chirurgie d’hyperplasie bénigne de la prostate. Il est peu fréquent et ne constitue qu’une faible proportion de l’ensemble des cancers de la prostate. Notre objectif était de décrire leurs profils épidémiologiques et histopathologiques. Matériel et méthodes Il s’agissait d’une étude multicentrique, rétrospective et descriptive sur 07 ans allant du 1er janvier 2018 au 31 décembre 2024. Elle a été menée à partir des archives de comptes rendus des laboratoires d’anatomie et cytologie pathologiques de l’Hôpital Général Idrissa Pouye, de l’Hôpital Aristide Le Dantec, de l’Hôpital militaire de Ouakam et de la Faculté de médecine de Dakar. Résultats Nous avons colligé 88 cas d’adénocarcinome prostatique incident sur pièces de RTUP et d’adénomectomie. L’âge moyen de nos patients était de 72,97±7,99 avec des extrêmes de 52 ans et 90 ans. La valeur moyenne du PSAt était de 34,23ng/mL et la médiane était de 18,49ng/mL. Le volume prostatique moyen était de 79,32 cc. Le score de Gleason 6 (3+3) était le plus fréquemment observé (55,68 %). Un engainement périnerveux a été noté chez 14,77 % des cas. Le stade pT1b était le plus représenté (76,14 %). Conclusion Au terme de cette étude, l’adénocarcinome prostatique incident est une affection encore observée dans nos régions malgré les avancées notées dans le diagnostic. Toutefois, la diversité des résultats rapportés dans la littérature suggère la nécessité d’une évaluation pronostique individualisée en utilisant les paramètres anatomopathologiques et biologiques afin d’optimiser la prise en charge.
This study aimed to investigate the occurrence, antimicrobial resistance profiles, and genetic characteristics of extended-spectrum beta-lactamase (ESBL)-producing E. coli in wastewater collected in Dakar, Senegal. All samples (n = 48) carried ESBL-producing isolates. The concentrations of ESBL-producing E. coli ranged from 1.4 × 10⁴ to 3.3 × 10⁵ CFU/100 mL, whereas the ratio of ESBL-producing E. coli among the total E. coli population varied between 0.2
Introduction: Horseshoe appendix duplex is an extremely rare anomaly with 16 cases de-scribed worldwide. The objective of this work is to bring the 17th global case and to do a re-view of the literature. Case Report: A 15-year-old boy, received for acute appendicitis. The abdominal ultrasound revealed acute appendicitis with a small collection around. Surgery was performed and we found a horseshoe appendix in the right iliac fossa with the two bases, each communicating with the cecum. Histological examination confirmed the digestive origin of the duplex appen-dix with the four typical histological layers. Conclusion: The horseshoe shape is the rarest of appendicular duplications. It is most often discovered during appendectomies.
Background:Carbapenem resistant Acinetobacter baumannii (CRAB) is considered a top priority pathogen by the World Health Organization and is also considered a leading cause of healthcare-associated infections (HAIs). This study aimed to investigate antimicrobial resistance (AMR) patterns and perform comprehensive whole-genome analysis on CRAB strains isolated from HAIs in Dakar, Senegal. Methods:CRAB isolates were collected from 2018 to 2021 in two major hospitals in Dakar and subjected to antimicrobial susceptibility tests followed by whole genome sequencing and comprehensive bioinformatic analysis to identify resistance genes, mobile genetic elements (MGEs) and perform phylogeny analysis. Results:The isolates demonstrated an alarming level of resistance to multiple classes of antibiotics, categorizing them as extremely drug resistant. Genetically, they present 5 distinct sequence types (ST1, ST52, ST85, ST107, and ST164), and an average of 71.9% accessory genes. They also present 30 to 51 genes associated with resistance to numerous classes of antibiotics. These genes included those responsible for resistance to β-lactams (such as bla OXA-23 , bla NDM-1 , bla OXA-51 and bla CTX-M15 ), to aminoglycosides (ant(3″)-IIa, aph(3″)-Ib, aph(3')-Ia), to fluoroquinolones (such as qnrS1, qnrB17, AdeFGH efflux pump), to fosfomycin (fos2A, fosA6, AbaF), and to tetracyclines (tet(A), tet(B), tet(39)). Conclusion:This pioneering study offers insight into the molecular mechanisms underlying carbapenem-resistant bacteria associated with HAIs in Senegal. These findings emphasize the critical need to implement surveillance programs particularly for carbapenem-resistant bacteria to gain a comprehensive understanding of their prevalence, propagation, impact on patient health outcomes, and prolonged hospital stays.
Background: The aims of this study were to assess the frequency of lower extremity arterial occlusive disease in HIV-positive patients on antiretroviral therapy by measuring the ankle-brachial index (ABI) and to examine the links between the HIV condition, antiretroviral therapy administration, and associated cardiovascular risk factors. Methods: This was a descriptive and analytical cross-sectional study with prospective data collection, conducted from May 1st to June 30th, 2022. Included were HIV-positive patients on antiretroviral therapy after signing an informed consent. The collected data included particularly the systematic and bilateral measurement of the ankle-brachial index. Any difference less than 0.05 was considered statistically significant. Results: Our study was conducted on 150 patients. There was a female predominance with a sex ratio of 0.58. The average age was 46.78±12.37 years. The main cardiovascular risk factors identified were dyslipidemia (51.6%), hypertension (19.5%), smoking (6.9%), and diabetes (3.4%). The duration of HIV infection over 15 years was most represented at 37.6%. The frequency of PAD was 55.2%. Among these, 37.6% had poorly compensated PAD. There was a correlation between PAD and smoking (p=0.029), dyslipidemia (p=0.02), and the duration of HIV infection between 6 and 10 years (p=0.039). Conclusion: Our study shows a very high frequency of PAD in patients living with HIV and highlights the importance of the ABI in screening for PAD in this patient group.
